↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Heyman B) "

Sökning: WFRF:(Heyman B)

Resultat 1-10 av 85

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
1.	Calabresi, PA, et al. (författare) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL 2007 Ingår i: Neurology. - : Ovid Technologies (Wolters Kluwer Health). - 1526-632X .- 0028-3878. ; 69:14, s. 1391-1403 Tidskriftsartikel (refereegranskat)
2.	Lee, PH, et al. (författare) Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders 2019 Ingår i: Cell. - : Elsevier BV. - 1097-4172 .- 0092-8674. ; 179:7, s. 1469- Tidskriftsartikel (refereegranskat)
3.	Voogt, ELK, et al. (författare) Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II) 2021 Ingår i: BJS open. - : Wiley. - 2474-9842. ; 5:3 Tidskriftsartikel (refereegranskat)
4.	Albertsen, B. K., et al. (författare) Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study 2019 Ingår i: Journal of Clinical Oncology. - 0732-183X. ; 37:19, s. 1638-1646 Tidskriftsartikel (refereegranskat)abstract PURPOSE Asparaginase is an essential drug in childhood acute lymphoblastic leukemia (ALL) therapy and is frequently given for months to obtain continuous asparagine depletion. We randomly assigned patients to continuous versus intermittent pegylated-asparaginase (PEG-asp) treatment, hypothesizing there would be decreased toxicity with unchanged efficacy. METHODS Children (median age, 4.2 years) treated for non-high-risk ALL according to the Nordic Society for Pediatric Hematology and Oncology ALL2008 protocol received five intramuscular PEG-asp injections (1,000 IU/m(2)) every two weeks and were then randomly assigned to additional three doses (6-week intervals [experimental arm], n = 309) versus 10 doses (2-week intervals [standard arm], n = 316). The primary end point was noninferior (6% margin) disease-free survival. Toxicity reduction was a secondary end point. Occurrence of asparaginase-associated hypersensitivity, pancreatitis, osteonecrosis, and thromboembolism were prospectively registered. RESULTS After a median follow-up of 4.1 years, the 5-year disease-free survival was 92.2% (95% CI, 88.6 to 95.8) and 90.8% (95% CI, 87.0 to 94.6) in the experimental and standard arms, respectively. The 3-year cumulative incidence of any first asparaginase-associated toxicity (hypersensitivity [n = 13]; osteonecrosis [n = 29]; pancreatitis [n = 24]; thromboembolism [n = 17]) was 9.3% in the experimental arm and 18.1% in the standard arm (P = .001). Asparaginase-associated toxicity reduction was confirmed in sex- and risk-group-adjusted Cox regression analysis stratified by age (>= 10 and < 10 years; hazard ratio, 0.48; P = .001). The experimental arm had the lowest incidences of all four toxicities, reaching significance for pancreatitis (6-month risk, 5.8% v 1.3%; P = .002). CONCLUSION The excellent cure rates and reduced toxicity risk support the use of intermittent PEG-asp therapy after the first 10 weeks in future childhood ALL trials that apply prolonged PEG-asp therapy.
5.	Altman, M, et al. (författare) 23 läkare om omskärelse av små pojkar. : 23 physicians comments on circumcision of small boys. 2014 Ingår i: Läkartidningen. - 0023-7205. ; 111:11, s. 494-5 Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
6.	Altman, M, et al. (författare) [23 physicians comments on circumcision of small boys: The Swedish Medical Association should take a more humble approach] 2014 Ingår i: Lakartidningen. - 0023-7205. ; 111:11, s. 494-5 Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
7.	Anastasopoulou, S, et al. (författare) Acute central nervous system toxicity during treatment of pediatric acute lymphoblastic leukemia: phenotypes, risk factors and genotypes 2022 Ingår i: Haematologica. - 1592-8721. ; 107:10, s. 2318-2328 Tidskriftsartikel (refereegranskat)
8.	Heyman, M, et al. (författare) A T cell lymphoblastic lymphoma patient with two malignant cell populations carrying different 9p deletions including the p16INK4 and p15INK4B genes: Clinical response to interferon-alpha therapy in one of the subclones 1996 Ingår i: Leukemia. - 0887-6924. ; 10:5, s. 909-917 Tidskriftsartikel (refereegranskat)
9.	Menounos, B., et al. (författare) Cordilleran Ice Sheet mass loss preceded climate reversals near the Pleistocene Termination 2017 Ingår i: Science. - : American Association for the Advancement of Science (AAAS). - 0036-8075 .- 1095-9203. ; 358:6364, s. 781-784 Tidskriftsartikel (refereegranskat)abstract The Cordilleran Ice Sheet (CIS) once covered an area comparable to that of Greenland. Previous geologic evidence and numerical models indicate that the ice sheet covered much of westernmost Canada as late as 12.5 thousand years ago (ka). New data indicate that substantial areas throughout westernmost Canada were ice free prior to 12.5 ka and some as early as 14.0 ka, with implications for climate dynamics and the timing of meltwater discharge to the Pacific and Arctic oceans. Early Bolling-Allerod warmth halved the mass of the CIS in as little as 500 years, causing 2.5 to 3.0 meters of sea-level rise. Dozens of cirque and valley glaciers, along with the southern margin of the CIS, advanced into recently deglaciated regions during the Bolling-Allerod and Younger Dryas.
10.	Applequist, SE, et al. (författare) Antibody production in mice deficient for complement receptors 1 and 2 canbe induced by IgG/Ag and IgE/Ag, but not IgM/Ag complexes. 2000 Ingår i: J Immunol. ; 165, s. 2398- Tidskriftsartikel (refereegranskat)

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 1-10 av 85

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (75); konferensbidrag (7); bok (1); annan publikation (1); forskningsöversikt (1)

Typ av innehåll: refereegranskat (69); övrigt vetenskapligt/konstnärligt (16)

Författare/redaktör: Heyman, M. (26); Schmiegelow, K. (13); Mataix-Cols, D (8); Jonsson, OG (8); Harila-Saari, A (7); Nordgren, A (6); visa fler...; Lund, B (5); Grander, D (5); Barbany, G (5); Zachariadis, V (5); Johansson, B (3); Zhivotovsky, B (3); Abrahamsson, Jonas, ... (3); Zeller, B (3); Grell, K. (3); Martin, J. (2); Kumar, S (2); Corcoran, M. (2); Jansson, L (2); Kleinau, S (2); Holmdahl, R (2); Lehmann, Sören (2); Walitza, S (2); Halmin, M (2); Forestier, Erik (2); Ruck, C (2); Fischler, B (2); Lagercrantz, H (2); Lausen, B (2); Buentke, E (2); Ilicki, A (2); Nisell, H (2); Pokrovskaja, K (2); Abrahamsson, J (2); Björkstén, B (2); Lundkvist, A (2); Bruchfeld, A (2); Albertsen, B. K. (2); Vettenranta, K. (2); Jonsson, O. G. (2); Golovleva, Irina (2); Altman, D (2); Altman, M (2); Böhm, F (2); Chrapkowska, C (2); Finder, M (2); Finkel, Y (2); Karpman, D (2); Mårtensson, T (2); Rosling, H (2); visa färre...

Lärosäte: Karolinska Institutet (44); Uppsala universitet (40); Göteborgs universitet (9); Umeå universitet (4); Lunds universitet (4); Stockholms universitet (3); visa fler...; Högskolan i Halmstad (1); Marie Cederschiöld högskola (1); visa färre...

Språk: Engelska (80); Odefinierat språk (4); Svenska (1)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (16); Naturvetenskap (5)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy